Monte Rosa Therapeutics Inc — Quarterly Financial Data (NASDAQ:GLUE) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Dividends per share ————— — Dividend yield % ————— — Payout ratio % ————— —

Nachrichten

Monte Rosa-Aktie legt nach positiven Studiendaten zu Prostatakrebs zu

Monte Rosa shares rise on prostate cancer trial results

Monte Rosa: Positive Studiendaten zu Prostatakrebs-Wirkstoff MRT-2359

Monte Rosa reports positive trial data for prostate cancer drug

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

Monte Rosa: Piper Sandler erhöht Kursziel auf 37 US-Dollar/n

Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler

Monte Rosa Therapeutics platziert Kapitalerhöhung über 300 Millionen US-Dollar

Monte Rosa Therapeutics prices $300 million public offering

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

Monte Rosa Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar